Stock Track | Teva Pharmaceutical Soars 15.52% on Strong Q3 Results and Improved 2025 Outlook

Stock Track

Nov 05

Shares of Teva Pharmaceutical Industries (TEVA) surged 15.52% in pre-market trading on Wednesday following the release of its impressive third-quarter results and updated guidance for 2025. The Israel-based pharmaceutical giant delivered a strong performance that exceeded analyst expectations, driven by robust sales of its key branded drugs.

Teva reported third-quarter non-GAAP earnings of $0.78 per diluted share, up from $0.69 a year earlier and significantly above the FactSet consensus estimate of $0.68. Revenue for the quarter rose 3% to $4.48 billion, surpassing analyst projections of $4.34 billion. The company's performance was bolstered by strong sales of its trio of branded drugs targeting migraines, Huntington's disease, and schizophrenia.

Adding to investor optimism, Teva raised its 2025 earnings guidance. The company now expects adjusted earnings per share in the range of $2.55 to $2.65, up from its previous forecast of $2.50 to $2.65. While Teva slightly narrowed its 2025 revenue projection to $16.8-$17.0 billion from $16.8-$17.2 billion, the market responded positively to the overall financial outlook. The company's CEO also mentioned a "clear path" to achieving a 30% operating margin by 2027, further boosting investor confidence in Teva's long-term prospects.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1156491456"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1156491456\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1156491456?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-05 23:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1156491456","market":"nz","top_or_hot":-1,"title":"Stock Track | Teva Pharmaceutical Soars 15.52% on Strong Q3 Results and Improved 2025 Outlook","media":"Stock Track","content":"<p>Shares of Teva Pharmaceutical Industries (TEVA) surged 15.52% in pre-market trading on Wednesday following the release of its impressive third-quarter results and updated guidance for 2025. The Israel-based pharmaceutical giant delivered a strong performance that exceeded analyst expectations, driven by robust sales of its key branded drugs.</p>\n\n<p>Teva reported third-quarter non-GAAP earnings of $0.78 per diluted share, up from $0.69 a year earlier and significantly above the FactSet consensus estimate of $0.68. Revenue for the quarter rose 3% to $4.48 billion, surpassing analyst projections of $4.34 billion. The company's performance was bolstered by strong sales of its trio of branded drugs targeting migraines, Huntington's disease, and schizophrenia.</p>\n\n<p>Adding to investor optimism, Teva raised its 2025 earnings guidance. The company now expects adjusted earnings per share in the range of $2.55 to $2.65, up from its previous forecast of $2.50 to $2.65. While Teva slightly narrowed its 2025 revenue projection to $16.8-$17.0 billion from $16.8-$17.2 billion, the market responded positively to the overall financial outlook. The company's CEO also mentioned a \"clear path\" to achieving a 30% operating margin by 2027, further boosting investor confidence in Teva's long-term prospects.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Teva Pharmaceutical Soars 15.52% on Strong Q3 Results and Improved 2025 Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Teva Pharmaceutical Soars 15.52% on Strong Q3 Results and Improved 2025 Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-05 23:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Teva Pharmaceutical Industries (TEVA) surged 15.52% in pre-market trading on Wednesday following the release of its impressive third-quarter results and updated guidance for 2025. The Israel-based pharmaceutical giant delivered a strong performance that exceeded analyst expectations, driven by robust sales of its key branded drugs.</p>\n\n<p>Teva reported third-quarter non-GAAP earnings of $0.78 per diluted share, up from $0.69 a year earlier and significantly above the FactSet consensus estimate of $0.68. Revenue for the quarter rose 3% to $4.48 billion, surpassing analyst projections of $4.34 billion. The company's performance was bolstered by strong sales of its trio of branded drugs targeting migraines, Huntington's disease, and schizophrenia.</p>\n\n<p>Adding to investor optimism, Teva raised its 2025 earnings guidance. The company now expects adjusted earnings per share in the range of $2.55 to $2.65, up from its previous forecast of $2.50 to $2.65. While Teva slightly narrowed its 2025 revenue projection to $16.8-$17.0 billion from $16.8-$17.2 billion, the market responded positively to the overall financial outlook. The company's CEO also mentioned a \"clear path\" to achieving a 30% operating margin by 2027, further boosting investor confidence in Teva's long-term prospects.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TEVA","symbol_name":"梯瓦制药","start_time":0,"source_url":"","article_id":"1156491456","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1156491456","pubTimestamp":1762356076,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Teva Pharmaceutical Industries (TEVA) surged 15.52% in pre-market trading on Wednesday following the release of its impressive third-quarter results and updated guidance for 2025. The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TEVA":"梯瓦制药"},"translate_title":"个股赛道|梯瓦制药大涨15.52%，Q3业绩强劲，2025年展望改善","themeId":"0e10452748c8c56d37b9e4059781f9d7","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEVA":1},"content_text":"Shares of Teva Pharmaceutical Industries (TEVA) surged 15.52% in pre-market trading on Wednesday following the release of its impressive third-quarter results and updated guidance for 2025. The Israel-based pharmaceutical giant delivered a strong performance that exceeded analyst expectations, driven by robust sales of its key branded drugs.\nTeva reported third-quarter non-GAAP earnings of $0.78 per diluted share, up from $0.69 a year earlier and significantly above the FactSet consensus estimate of $0.68. Revenue for the quarter rose 3% to $4.48 billion, surpassing analyst projections of $4.34 billion. The company's performance was bolstered by strong sales of its trio of branded drugs targeting migraines, Huntington's disease, and schizophrenia.\nAdding to investor optimism, Teva raised its 2025 earnings guidance. The company now expects adjusted earnings per share in the range of $2.55 to $2.65, up from its previous forecast of $2.50 to $2.65. While Teva slightly narrowed its 2025 revenue projection to $16.8-$17.0 billion from $16.8-$17.2 billion, the market responded positively to the overall financial outlook. The company's CEO also mentioned a \"clear path\" to achieving a 30% operating margin by 2027, further boosting investor confidence in Teva's long-term prospects.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}